REPEATED DOSES OF LPJ-394 IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

$19,199M01FY2000RRNIH

Case Western Reserve University, Cleveland OH

Investigators

Linked publications & trials

Paper 38974693 Paper 38749325 Paper 38551823 Paper 38355559 Paper 38293196 Paper 38150746 Paper 37726016 Paper 37614188 Paper 37573327 Paper 37017634 Paper 36878957 Paper 36623610 Paper 36288905 Paper 35728925 Paper 35705018 Paper 35686375 Paper 35253117 Paper 35197258 Paper 34670321 Paper 34620218 Paper 34288880 Paper 34232841 Paper 34166655 Paper 33836029 Paper 33746861 Paper 33729508 Paper 33617797 Paper 33592520 Paper 33478957 Paper 33388403 Paper 33161213 Paper 33156902 Paper 33112825 Paper 33073088 Paper 33042596 Paper 32905775 Paper 32896524 Paper 32870816 Paper 32670032 Paper 32605069 Paper 32598452 Paper 32446491 Paper 32245884 Paper 32182883 Paper 32170957 Paper 32123584 Paper 32111975 Paper 31967891 Paper 31691959 Paper 31427096 Paper 30731481 Paper 30655182 Paper 30631138 Paper 30487263 Paper 30354704 Paper 30348535 Paper 30294505 Paper 30282103 Paper 30037422 Paper 29872859 Paper 29510423 Paper 29370333 Paper 29339903 Paper 29190847 Paper 29155504 Paper 29110761 Paper 29051146 Paper 28830083 Paper 28724164 Paper 28647272 Paper 28572159 Paper 28522317 Paper 28366517 Paper 28283553 Paper 28279433 Paper 28199816 Paper 28179267 Paper 27886650 Paper 27836424 Paper 27824768 Paper 27743977 Paper 27699244 Paper 27577874 Paper 27455401 Paper 27434583 Paper 27423510 Paper 27398706 Paper 27321945 Paper 27267668 Paper 27174555 Paper 27151903 Paper 27142425 Paper 27140936 Paper 27126296 Paper 27120478 Paper 27074126 Paper 27054932 Paper 26855099 Paper 26788786 Paper 26711738

Abstract

This is a prospective multi-center double-blind, placebo-controlled Phase II-III trial in which an investigational new drug, LPJ 394, will be tested for its ability to reduce the production of antibodies to double stranded DNA (anti-dsDNA) and limit flare-ups of active renal disease in patients with lupus nephritis. The subjects will receive medication for 52 weeks, after which there will be a six month period of follow-up to assess clinical lupus activity, anti-DNA levels and health status.

View original record on NIH RePORTER →